UBS AM’s Jade Biosciences JBIO Stock Holding History

UBS AM’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$477K	Buy	21,486 +20,993	+4,258%	+$438K	﹤0.01%	2554
2026 Q1	$6.93K	Buy	493 +283	+135%	+$4.1K	﹤0.01%	3390
2025 Q4	$3.24K	Buy	+210	New	+$2.46K	﹤0.01%	3057

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's JBIO Position: Q2 2026 in Review

UBS AM increased its Jade Biosciences (JBIO) stake by 4,258% in Q2 2026, buying an estimated $438K and bringing the position to 21,486 shares worth $477K. The position accounts for ﹤0.01% of the portfolio, ranked #2554.

UBS AM first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

UBS AM held 21,486 shares of Jade Biosciences worth $477K as of Q2 2026.
UBS AM bought 20,993 Jade Biosciences shares in Q2 2026, an estimated $438K.
Jade Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2554 holding.
UBS AM first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.